Alprostadil Injection

Alprostadil Injection 500mcg/1mL is a prescription prostaglandin E1 (PGE1) medicine containing 500 micrograms of alprostadil in each 1mL ampoule. This high-strength formulation is used by specialist healthcare teams to temporarily maintain patency of the ductus arteriosus in neonates and infants with certain critical congenital heart defects, helping maintain pulmonary or systemic blood flow until definitive corrective or palliative treatment can be performed.

Current U.S. FDA labeling identifies PROSTIN VR PEDIATRIC® as alprostadil injection containing 500 micrograms per mL. UK medicines information lists Prostin VR 500 micrograms/mL, while Australia's TGA lists both PROSTIN VR and the newer NEUPEDIX 500 microgram/1mL presentations.

Alprostadil is the generic medicine name, not a brand name. Prostin VR, Prostin VR Pediatric and Neupedix are specific branded/product presentations in particular markets. Brand names, manufacturers and regulatory registrations vary by country.

Product Information

Generic Name

Alprostadil

Active Ingredient

Alprostadil (Prostaglandin E1 / PGE1)

Strength

500 micrograms/mL

Total Amount

500 micrograms per 1mL ampoule

Dosage Form

Sterile concentrate for solution for infusion

Route

Intravenous infusion or specialist intra-arterial administration according to the applicable product information

Drug Class

Prostaglandin / Vasodilator

ATC Code

C01EA01

Primary Specialist Use

Maintaining ductus arteriosus patency in neonates with selected congenital heart defects

Prescription Status

Prescription-only / hospital specialist medicine

Common Pack

1mL ampoules; pack sizes vary by manufacturer and market

U.S. Brand Example

PROSTIN VR PEDIATRIC®

UK Brand Example

Prostin VR

Australian Product Examples

PROSTIN VR and NEUPEDIX

Active Ingredient per Ampoule

500 micrograms alprostadil

Alprostadil 500mcg Injection for Ductus Arteriosus

The ductus arteriosus is a fetal blood vessel connecting the pulmonary artery and aorta. It normally begins to close after birth.

In some neonates with critical congenital heart disease, however, continued ductal patency is essential for maintaining adequate pulmonary or systemic circulation.

Alprostadil can relax the smooth muscle of the ductus arteriosus and temporarily maintain its patency. This can provide a bridge to cardiac catheterization, surgery or other definitive treatment.

Alprostadil 500mcg/1mL Concentration

Each 1mL ampoule contains:

500 micrograms alprostadil / 1mL

This is equivalent to:

• 500mcg/mL
• 0.5mg/mL
• 500 micrograms in each 1mL ampoule

The formulation is highly concentrated and is generally diluted before administration according to the applicable product instructions and the infusion system used. UK product information specifically requires careful preparation of dilutions.

Alprostadil and Apnoea

Apnoea is a major safety consideration with neonatal alprostadil infusion.

The FDA states that apnoea most often occurs during the first hour of infusion and that treatment should be administered where ventilatory assistance is immediately available. UK prescribing information similarly requires use by appropriately trained healthcare professionals with access to pediatric intensive care.

Alprostadil Injection Monitoring

Because alprostadil is used in critically ill neonates, treatment requires continuous specialist monitoring.

Depending on the clinical situation, the medical team may monitor:

• Respiratory status
• Oxygenation
• Blood pressure
• Heart rate
• Blood gases
• Blood pH
• Cardiac function
• Clinical response to ductal opening

The treatment objective is to use the lowest effective infusion rate for the shortest appropriate period while the infant receives definitive management.

Alprostadil 500mcg/1mL vs Alprostadil for Erectile Dysfunction

This distinction is very important for ecommerce and SEO.

Alprostadil is also used in completely different formulations for erectile dysfunction. Those products are generally supplied at much lower microgram strengths, such as 10mcg, 20mcg or 40mcg formulations.

For example, UK Caverject products contain 10mcg or 20mcg of alprostadil per dose after reconstitution and are indicated for erectile dysfunction.

Alprostadil 500mcg/1mL should therefore not be described as a standard erectile-dysfunction injection. The 500mcg/mL formulation identified in current U.S. and UK product information is a specialist neonatal infusion product for maintaining ductus arteriosus patency.

Alprostadil Injection Brands

Because alprostadil is the generic medicine name, the brand name should be kept separate from the generic product description.

Examples include:

• Prostin VR / PROSTIN VR PEDIATRIC® — specific branded products containing alprostadil 500mcg/mL in relevant markets
• Neupedix — alprostadil 500 microgram/mL product listed in the UK and Australia
• Caverject — a different alprostadil formulation used for erectile dysfunction and supplied at substantially lower microgram strengths

Current UK medicines information lists both Neupedix 500 micrograms/mL and Prostin VR 500 micrograms/mL under alprostadil, while Australia's TGA lists NEUPEDIX 500 microgram/1mL and PROSTIN VR 500 microgram/1mL as registered medicines.

Alprostadil Injection Availability & Ordering

Alprostadil Injection 500mcg/1mL has strong specialist pharmaceutical search intent around the generic ingredient, concentration, ampoule presentation and established branded equivalents.

Commercial search themes include:

Alprostadil Injection 500mcg, Alprostadil 500mcg/1mL, Alprostadil 500 Micrograms Injection, Alprostadil 500mcg Injection, Alprostadil 500mcg/mL, Alprostadil Injection Ampoule, Alprostadil 500mcg Ampoule, Generic Alprostadil Injection, Prostin VR 500mcg, Prostin VR Pediatric 500mcg and Neupedix 500mcg.

Availability, manufacturer, prescription classification, packaging and authorization differ between the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

For international pharmaceutical ecommerce, the actual manufacturer and regulatory authorization of the product should be verified for the destination market. Alprostadil 500mcg/mL is a specialist hospital medicine and should not be presented as an ordinary consumer injectable.

How it works

Alprostadil is a synthetic form of prostaglandin E1 (PGE1).

It produces several pharmacological effects, including vasodilation and relaxation of susceptible smooth muscle. The ductus arteriosus is particularly sensitive to prostaglandin E1.

In neonates with ductal-dependent congenital heart disease, this effect can help prevent or reverse ductal closure and maintain blood flow while definitive treatment is arranged.

The 500mcg/1mL alprostadil formulation is primarily a specialist neonatal cardiovascular medicine.

It is used to temporarily maintain ductus arteriosus patency in infants whose circulation depends on the ductus remaining open. Conditions listed in UK product information include certain cases of:

• Pulmonary atresia
• Pulmonary stenosis
• Tricuspid atresia
• Tetralogy of Fallot
• Interrupted aortic arch
• Coarctation of the aorta
• Aortic stenosis
• Aortic atresia
• Mitral atresia
• Transposition of the great vessels

The precise indication depends on the infant's cardiac anatomy and the applicable product authorization.

This product should not be self-administered or dosed outside a specialist neonatal/cardiac setting.

The UK SmPC states that infusion is generally initiated at 0.05–0.1 micrograms/kg/minute, followed by reduction to the lowest rate that maintains the desired therapeutic response. Lower infusion rates may be used in selected circumstances under specialist supervision.

Because alprostadil dosing is weight-based and depends on the infant's cardiac physiology and response, the actual infusion rate must be determined and monitored by the treating specialist team.

Alprostadil Injection Administration

Alprostadil 500mcg/mL is a concentrate for solution for infusion, rather than a routine direct-dose injection for general outpatient use.

The UK product information specifies administration by:

• Intravenous drip
• Constant-rate infusion pump
• Specialist intra-arterial catheter administration in selected neonatal circumstances

The diluted solution should be prepared according to the manufacturer's instructions.

Alprostadil can cause clinically significant adverse effects, particularly in critically ill neonates.

Reported or clinically important reactions include:

• Apnoea
• Hypotension
• Flushing
• Fever
• Bradycardia or tachycardia
• Seizures
• Respiratory depression
• Gastrointestinal effects
• Edema
• Cardiac rhythm disturbances

Apnoea is particularly important. The FDA label reports that apnoea occurs in approximately 10–12% of neonates treated with PROSTIN VR PEDIATRIC, with higher risk in neonates weighing less than 2kg at birth.